Supplementary Table S4 showed that after fVII-tPDT treatment (2 μM SnCe6 in fVII-SnCe6 and 36 J/cm2), both the CD133+ CSCs and CD133- cancer cells were completely eradicated (0% survival) as determined by the clonogenic assay, whereas the membrane-staining assay, due to its limitations that crystal violet would stain any cellular membrane, either viable cells or cell debris (see Figure 4e–4f and Supplementary Figure S6), so that the membrane staining assay showed that the survival % of CD133+ CSCs was ~31% and CD133- H460 was ~40% (p=0.0171). The gene discussed is PROM1; the disease is cancer.